Simple stereocontrolled synthesis of salinosporamide A
申请人:Corey J. Elias
公开号:US20050228186A1
公开(公告)日:2005-10-13
A simple and effective stereocontrolled synthesis of salinosporamide A (1)
has been developed which follows the pathway outlined in the Figure. The process, the first total synthesis of salinosporamide A, is capable of providing the compound in substantial quantities for further biological studies. In addition to the method of Scheme I, the present invention also includes several novel synthetic intermediate compounds, several intermediate steps of the preferred synthetic process; and the uses of these compounds in the preparation of synthetic derivatives of the compound Salinosporamide A. Salinosporamide A is of special interest as a synthetic target because of its protein in vitro cytotoxic activity against many tumor cell lines (IC
50
values of 10 nM or less).
已经开发出一种简单而有效的立体控制合成方法,用于制备Salinosporamide A (1),该方法遵循图中概述的途径。这个过程是对Salinosporamide A的首次全合成,能够提供大量的化合物用于进一步的生物研究。除了方案I的方法之外,本发明还包括几种新颖的合成中间体化合物,首选合成过程的几个中间步骤;以及这些化合物在制备Salinosporamide A的合成衍生物中的用途。Salinosporamide A作为合成目标具有特殊的意义,因为它在体外对许多肿瘤细胞系的蛋白细胞毒活性(IC50值为10 nM或更低)。
Analogs of Salinosporamide A
申请人:Corey J. Elias
公开号:US20070161693A1
公开(公告)日:2007-07-12
Disclosed herein are analogs of Salinosporamide A, having the Formulae Ia-IVa as follows:
Like Salinosporamide A, the compounds of the present invention will inhibit the proteasome, an intracellular enzyme complex that destroys proteins the cell no longer needs. Without the proteasome, proteins would build up and clog cellular machinery. Fast-growing cancer cells make especially heavy use of the proteasome, so thwarting its action is a compelling drug strategy.
US7183417B2
申请人:——
公开号:US7183417B2
公开(公告)日:2007-02-27
US7511156B2
申请人:——
公开号:US7511156B2
公开(公告)日:2009-03-31
A Simple Stereocontrolled Synthesis of Salinosporamide A
作者:Leleti Rajender Reddy、P. Saravanan、E. J. Corey
DOI:10.1021/ja048613p
日期:2004.5.1
A simple and effective stereocontrolled synthesis of salinosporamide A has been developed. This process, the first synthesis of salinosporamide A, is capable of providing the compound in substantial quantities for further biological studies. Salinosporamide A was of special interest as a synthetic target because of its potent in vitro cytotoxic activity against many tumor cell lines (IC(50) values